Idiopathic pulmonary fibrosis treatment is a type of interstitial lung disease in which the lung tissues become scarred and changes lung's ability to function normally. It is a progressive disease, over months to years, the normal lung tissue is replaced by more heavily scarred lung tissue, which makes it difficult to breathe and deliver needed oxygen to the body. Cause of disease may be smoking, genetics or working around dust or fumes for long period. The symptoms of disease are dry cough, shortness of breath, fatigue and weight loss.
The idiopathic pulmonary fibrosis treatment market is expected to grow exponentially in the forecast period owing to the factors such as growth in prevalence of fibrotic disease, increasing geriatric population and increase in cigarette smoking population. Furthermore, the introduction of effective drug treatment for idiopathic pulmonary fibrosis is anticipated to offer significant growth opportunities in the market during the forecast period.
The "Global Idiopathic Pulmonary Fibrosis Treatment Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the idiopathic pulmonary fibrosis treatment market with detailed market segmentation by drug type, formulation, distribution channel and geography. The global idiopathic pulmonary fibrosis treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading idiopathic pulmonary fibrosis treatment market players and offers key trends and opportunities in the market.
The global idiopathic pulmonary fibrosis treatment market is segmented on the basis of drug type, formulation and distribution channel. Based on drug type, the market is classified as pirfenidone and nintedanib. Based on formulation the market is bifurcated into tablets and soft capsules. On the basis of distribution channel the idiopathic pulmonary fibrosis treatment market is classifies as hospital pharmacy, retail pharmacy and online pharmacy. REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global idiopathic pulmonary fibrosis treatment market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The idiopathic pulmonary fibrosis treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting idiopathic pulmonary fibrosis treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Idiopathic pulmonary fibrosis treatment market in these regions.
The reports cover key developments in the idiopathic pulmonary fibrosis treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from idiopathic pulmonary fibrosis treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for idiopathic pulmonary fibrosis treatment market in the global market. Below mentioned is the list of few companies engaged in the Idiopathic pulmonary fibrosis treatment market.
The report also includes the profiles of key idiopathic pulmonary fibrosis treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- AdAlta Limited
- ANGION BIOMEDICA CORP.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Cipla Inc.
- F. Hoffmann-La Roche Ltd
- MediciNova, Inc.
- Promedior, Inc.
- Prometic Life Sciences Inc.
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
This text is related
to segments covered.
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
This text is related
to country scope.
1. AdAlta Limited
2. ANGION BIOMEDICA CORP.
4. Boehringer Ingelheim International GmbH
5. Bristol-Myers Squibb Company
6. Cipla Inc.
7. F. Hoffmann-La Roche Ltd
8. MediciNova, Inc.
9. Promedior, Inc.
10. Prometic Life Sciences Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)
Enteral and Parenteral Medical Nutrition Market
Forecast to 2028 - Global Analysis by Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer's Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole–Source), Form (Liquid, Powder, and Semi–Solid), Product Type (General and Disease–Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18–60 Years, 3–18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
CIN & HR-HPV Treatment Market
Forecast to 2028 - Global Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)
Pharmaceutical Fluid Handling Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Offering (Equipment & Solutions and Services), Tubing (Thermoplastic Elastomers, Polyvinyl Chloride, and Silicone), Application (Fluid Handling & Management, Fluid Preparation, Integration & Automation, Buffer Management, and Others), Usage (Cough Syrup, Intravenous Product, Complex Active Pharmaceutical Ingredients, and Others), and End User (Biotechnology Companies, Pharmaceutical & Medical Companies, and Others)
Enteral Medical Nutrition Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]
Glycomic Therapeutics Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]